Japanese encephalitis virus (JEV) is the major cause of viral encephalitis 28 in South East Asia. It has been suggested that JEV gets access to the central 29 nervous system (CNS) as a consequence of a preceding inflammatory process 30 which leads to the blood-brain barrier (BBB) disruption and viral neuroinvasion. However, what happens at early times of JEV contact with the BBB is poorly 32 understood. In the present work, we evaluated the ability of both a virulent and 33 a vaccine strain of JEV (JEV RP9 and SA14-14-2, respectively) to cross an in 34 cellulo human BBB model consisting of hCMEC/D3 human endothelial cells 35 cultivated on permeable inserts above SK-N-SH human neuroblastoma cells. 36
3

INTRODUCTION 52
Flaviviruses such as Japanese encephalitis virus (JEV) are arthropod-53 borne viruses (arbovirus) that are transmitted through the bite of an infected 54 mosquito and may cause serious human diseases [1] . JEV is the main 55 causative agent of viral encephalitis in South East Asia, with an annual 56 incidence of around 68 000 cases [2] . About 30% of the cases are fatal, and 57 half of the survivors present neurological sequelae [3] . To date, no specific 58 treatment against JEV exists [3] . However, Japanese encephalitis is a 59 preventable disease as vaccines have been developed: the live-attenuated JEV 60 SA14-14-2 strain, as well as a recombinant vaccine and an inactivated one, 61 also based on the JEV SA14-14-2 strain [4, 5] . The live-attenuated vaccine was 62 obtained empirically after several passages of the JEV SA14 virulent strain in 63 primary hamster kidney cells [6] . Although highly efficient, cases of post-vaccine 64 encephalitis were also reported [7] , suggesting that the vaccine strain JEV 65 SA14-14-2 is still neurovirulent in humans. 66 JEV has a positive-sense RNA genome encoding a single polyprotein 67 flanked by two untranslated regions (UTR) at its 5' and 3' ends. This polyprotein 68 is co-and post-translationally cleaved into three structural proteins (capsid C, 69 membrane prM and envelope E) involved in viral particle assembly and 70 antigenicity and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, 71 NS4B and NS5) involved in genome replication, viral particle assembly and 72 evasion of innate immunity [1] . Due to an error-prone NS5 polymerase that 73 frequently introduces mutations in the viral genome during replication, a 74 8 6516 were diluted the next day in 50µL of EndoGro medium supplemented with 2% 182 FBS, heated at 37°C and then added to the cells. Cells were incubated at 37°C 183 until collection. 184
Focus-forming assay (FFA) 185
Vero cells were seeded in 24-well plates. Ten-fold dilutions of virus 186 samples were prepared in DMEM and 200µL of each dilution was added to the 187 cells. The plates were incubated for 1h at 37°C. Unabsorbed virus was removed 188 and 800µL of DMEM supplemented with 0.8% carboxymethyl cellulose (CMC), 189 5 mM HEPES buffer, 36 mM sodium bicarbonate, and 2% FBS were added to 190 each well, followed by incubation at 37°C for 48h for JEV RP9 or for 72h for 191 JEV SA14-14-2. The CMC overlay was aspirated, and the cells were washed 192 with PBS and fixed with 4% paraformaldehyde for 20 min, followed by 193 permeabilization with 0.1% Triton X-100 for 5 min. After permeabilization, the 194 cells were washed with PBS and incubated for 1h at room temperature with 195
anti-E antibody (4G2), followed by incubation with HRP-conjugated anti-mouse 196 
Quantification of JEV RNA copies number 257
Total RNA from JEV BBB-crossing samples was extracted using 258
NucleoSpin®RNA kit (Macherey-Nagel; 740955.50) according to the 259 manufacturer's instructions. The number of JEV RNA copies present in BBB-260 crossing samples was determined by RT-qPCR using TaqMan® Fast Virus 1-261
Step Master Mix kit (Applied Biosystems®, 4444432) Neuroblastoma SK-N-SH cells are susceptible to both the virulent JEV RP9 300 strain and the SA14-14-2 attenuated strain [27, 30] . However, a direct 301 comparison between replication of these two JEV strains in that cell line has not 302 been described. We thus evaluated replication of each JEV strain in SK-N-SH 303 cells at 24 and 48 hpi (Fig. 2) . As expected, both JEV strains infected the 304 neuroblastoma-derived cell line as demonstrated by the detection of a viral 305 antigen (NS5 protein) through immunofluorescence assays ( Fig. 2A) . However, 306 the viral progeny of JEV SA14-14-2 vaccine strain produced in SK-N-SH cells at 307 24 and 48 hpi was significantly lower than that of JEV RP9 (1.7 and 1.2 log10 308 less at 24 and 48 hpi respectively, Fig. 2B ), suggesting that JEV SA14-14-2 is 309 less neurovirulent than JEV RP9 in human cell cultures. 310
311
Neither JEV RP9 nor JEV SA14-14-2 infects hCMEC/D3 cells after they 312 form a BBB. In order to examine the susceptibility of our hCMEC/D3 BBB 313 model to JEV infection, the cells were grown 6 days on coverslips to allow the 314 BBB to form, then inoculated with either RP9 or SA14-14-2 JEV strain (Fig. 3) . 315
The presence of the NS5 viral protein as infection evidence was assessed by 316 immunofluorescence microscopy as described in the Material and Methods 317 section. No fluorescence signal was observed in hCMEC/D3 BBB-forming 318 monolayer either at 24 or 48 hpi (Fig. 3A) . Surprisingly, hCMEC/D3 cells could 319 be infected by either JEV strains when they were inoculated after only one day 320 of culture (ie not forming of a BBB), as detected through the same 321 immunofluorescence approach (Fig. 3B) . Moreover, in this condition, both JEV 322 14 strains produced infectious viral progeny in hCMEC/D3, although the RP9 viral 323 titer was significant higher by around 2 log than that observed for SA14-14-2 324 (Fig. 3C) . These results suggest that hCMEC/D3 cells are not susceptible to 325 JEV infection when they already have formed a barrier, but they are JEV 326 permissive before tight junctions formation. 327
328
Neither JEV RP9 nor JEV SA14-14-2 disrupts the BBB when added for 6h. 329
It has been suggested that JEV infects brain tissue cells as a consequence of a 330 preceding inflammatory process which leads to the BBB disruption and viral 331 neuroinvasion [31, 32] . However, the very early events of JEV BBB crossing are 332 still poorly understood. In order to evaluate the neuroinvasive ability of JEV in 333 our BBB model at early times post-addition, hCMEC/D3 cells cultivated on 334 permeable inserts to form a BBB above SK-N-SH cells monolayer were 335 exposed to either JEV RP9 or SA14-14-2 virus addition (MOI=1 or 10; Fig. 4) . 336
The permeability of the BBB at 6 hpi in the presence of the 2 different JEV 337 strains did not show a significant difference when compared to that of the mock-338 infected condition (Fig. 4A) , suggesting that the BBB model was not disturbed 339 either by the JEV strains or the MOIs used. 340
341
More JEV RP9 infectious particles may cross the in cellulo BBB model 342 than JEV SA14-14-2. 343
Since the BBB permeability was not affected by the addition of either virus, we 344 examined the viral crossing of each strain by evaluating the quantity of viral 345 RNA and infectious particles in the supernatants under the inserts (Fig. 4B and  346 C). The number of viral RNA copies detected for both viruses was 1.7 log10 347 higher when a MOI of 10 was used in comparison to a MOI of 1 (Fig. 4B) , 348
suggesting that the higher the JEV viral load, the greater the number of viral 349 particles crossing the BBB. Of note, there was no significant difference in the 350 viral RNA copy number between the JEV strains for each MOI (MOI=1 or =10, 351 Fig. 4B) . However, the infectious titers of the JEV particles that crossed the 352 BBB was surprisingly different between the RP9 and SA14-14-2 strains, as 353 about 3 times more RP9 infectious particles where found in the supernatants 354 under the inserts than SA14-14-2 when an MOI of 1 was used, and close to 10 355 times for a MOI of 10 (Fig. 4C) . Calculation of the specific infectivity for JEV 356 RP9 and SA14-14-2 strains as the ratio between the detected JEV RNA copy 357 number per infectious focus-forming unit did not show a significant difference 358 between the 2 viral stocks (Fig. 5A) . Interestingly, the specific infectivity for the 359 RP9 BBB-crossing samples was significantly lower than that observed for the 360 vaccine strain SA14-14-2 with a 3 to 10 fold decrease for MOI=1 and =10 361 respectively (Fig. 5B) In this study, we have used an in cellulo model of a human BBB to 378 compare JEV RP9 virulent and JEV SA14-14-2 vaccine strain ability to cross 379 the BBB at early times post-addition. We have shown that both JEV RP9 and 380 SA14-14-2 are able to cross the BBB without disrupting it at 6 hpi ( Fig. 4) . This 381 finding is very relevant because it suggests that JEV could be able to get 382 access to the CNS and establish a primary infection there without the preceding 383 need of inflammatory cytokines that could lead to BBB disruption prior CNS 384 cells viral infection as it is currently thought [31, 32] . 385 Moreover, the fact that both JEV RP9 and SA14-14-2 strains crossed the 386 BBB without infecting its endothelial cells, nor disrupting the barrier, also 387 suggests that JEV is able to cross the BBB in a transcellular way through the 388 endothelial cells or in a paracellular way between the endothelial cells. These 389 observations are consistent with other studies conducted in vivo in mice and 390 monkeys [11, 16, 36] . Observations of JEV-infected suckling mice brain by 391 electron-microscopy suggested that JEV crosses the BBB endothelial cells by 392 transcytosis [14] . Regardless of these observations, currently there is no 393 published data to support this hypothesis from biochemical, genetics or 394 functional approaches. The combination of these approaches, together with the 395 use of our in cellulo BBB model and JEV strains with different neuroinvasive 396 capabilities such as the ones used in this work would be useful to identify which 397 cell mechanisms are "highjacked" by these pathogens to cross the BBB. 398
Interestingly, our specific infectivity data suggest that JEV RP9 infectious 399 particles crossed the BBB more efficiently than JEV SA14-14-2 (Fig. 5) . 400
Comparison of the transcriptome from hCMEC/D3 cells forming a BBB to which 401 either JEV RP9, SA14-14-2 or no virus was added for 6h showed no significant 402 difference in the levels of gene expression (fold-change threshold of 2, data not 403 shown). This suggests that an early cell response is not responsible for the 404 differential BBB crossing of JEV RP9 versus JEV SA-14-14-2 particles we 405 observed (Fig. 4C) , and that it most likely stems from viral factors. It is also 406 possible that the difference in the JEV RP9 and SA14-14-2 infectious particles 407 ability to cross the in cellulo BBB relies on specific protein interactions, for 408 example, interaction of the viral particle with a strain-specific cell surface 409 receptor for viral entry. A full characterization of the viral particles that are able 410 to cross the BBB including by deep-sequencing of their RNA content and 411 examining the endothelial cells forming the BBB after contact with either virus 412 by electron microscopy, together with uncovering specific cell receptor(s) for 413 JEV strains could help solving these issues. 414 Surprisingly, we found that hCMEC/D3 were permissive to both RP9 and 415 SA14-14-2 strains only when the BBB formation was not completed (Fig. 3B) RNA was extracted and receptors (B) and transporters (C) typical of the BBB-577 encoding genes were quantified by RT followed by qPCR as described in 578
Material and Methods. Graphs show the results from two independent 579 experiments performed by duplicates. 580 cultured on coverslips for either 6 days (A) or 1 day (B), so that they form or not 593 a BBB respectively. Cells were then inoculated with the indicated JEV strain at 594 MOI=0.1 and analyzed at 24 and 48 hpi by immunofluorescence staining for the 595 presence of the NS5 protein (in green). The images were taken at a x200 596 magnification, the cells nuclei are stained by DAPI (in blue). C) Supernatants 597 from hCMEC/D3 cells that do not form a BBB and infected by JEV RP9 (black 598 bar) or JEV SA14-14-2 (white bar) were collected at 24 and 48 hours post-599 infection and their viral titer was determined as described in Material and 600
Methods. The arithmetic means ± standard deviation of three independent 601 experiments performed by triplicate is shown. Asterisks indicate a significant 602 difference between RP9 and SA14-14-2 in each one of the times post-infection 603 evaluated (**, P < 0.01, ***, P < 0.001). 604 Methods. B) In cellulo BBBs were generated as indicated above and either JEV 611 strain was added at MOI=1 or =10. After 6 h, total RNA was extracted from JEV 612 BBB-crossing samples under the inserts and the number of JEV RNA copies 613 was determined by RT-qPCR as described in Material and Methods. C) Either 614 JEV RP9 (black bars) or SA14-14-2 (white bars) BBB-crossing samples were 615 collected after 6 h post-addition and their viral titer was determined as described 616 in Material and Methods. The arithmetic means ± standard deviation of at least 617 two independent experiments performed by triplicate is shown. Asterisks 618 indicate a significant difference between the RP9 and SA14-14-2 titers in each 619 one of the MOIs evaluated in the BBB-crossing experiments (****, P < 0.0001). 620 either JEV RP9 or JEV SA14-14-2 stocks used for the JEV BBB-crossing 623 experiments were determined as described in Material and Methods. The 624 specific infectivity of both stocks was calculated by dividing the viral RNA copies 625 number/ml by the FFU/ml of each viral stocks. B) The specific infectivity of the 626 JEV RP9 and SA14-14-2 BBB-crossing samples was calculated as indicated 627 above using the data from Fig. 4B and 4C . The arithmetic means ± standard 628 deviation of at least two independent experiments performed by triplicate is 629 
